Lab Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

AstraZeneca

AstraZeneca: Third Quarter and Nine Months Results 2009

Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.

-US sales of Toprol-XL, benefiting from withdrawal of generic products, accounted for 3 percent of global revenue growth at CER.-US sales of Novel Influenza A (H1N1) vaccine totalled $152 million in the third quarter, accounting for 2 percent of global revenue growth at CER. -Emerging Markets revenue was up 15 percent at CER; on track for double-digit growth for the full year.

Core operating profit in the third quarter increased by 29 percent at CER to $3,609 million on revenue growth and operational...

• View Other Issues of Lab Business Week
  
• View Other NewsRx Publications